Regeneron Pharmaceuticals (REGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 09-2019 | 06-2019 | 03-2019 | 12-2018 | 09-2018 | |
| Sales | 1,743,700 | 1,577,800 | 1,372,600 | 362,600 | 1,663,500 |
| Cost of Goods | 225,500 | 145,800 | 172,100 | 100,500 | 110,400 |
| Gross Profit | 1,518,200 | 1,432,000 | 1,200,500 | 262,100 | 1,553,100 |
| Operating Expenses | 780,200 | 1,117,200 | 720,600 | -455,500 | 926,600 |
| Operating Income | 738,500 | 315,600 | 480,000 | 718,100 | 626,900 |
| Interest Expense | 7,800 | 8,000 | 7,700 | 7,500 | 7,400 |
| Other Income | 37,800 | -82,900 | 73,800 | -34,500 | 16,400 |
| Pre-tax Income | 768,500 | 224,700 | 546,100 | 676,100 | 635,900 |
| Income Tax | 98,900 | 31,600 | 85,000 | -144,200 | 41,200 |
| Net Income Continuous | 669,600 | 193,100 | 461,100 | 820,300 | 594,700 |
| Net Income | $669,600 | $193,100 | $461,100 | $820,300 | $594,700 |
| EPS Basic Total Ops | 6.12 | 1.77 | 4.23 | 7.59 | 5.50 |
| EPS Basic Continuous Ops | 6.12 | 1.77 | 4.23 | 7.59 | 5.51 |
| EPS Diluted Total Ops | 5.86 | 1.68 | 3.99 | 7.14 | 5.17 |
| EPS Diluted Continuous Ops | 5.86 | 1.69 | 3.99 | 7.15 | 5.17 |
| EBITDA(a) | $791,400 | $367,700 | $531,000 | $760,900 | $662,300 |